Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 14, Issue 4, 2009, Pages 274-282

  Florentin, Matilda ^a   Kostapanos, Michael S ^a   Nakou, Eleni S ^a   Elisaf, Moses ^a   Liberopoulos, Evangelos N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Dyslipidemia; Ezetimibe; Obesity; Orlistat; Rimonabant

Indexed keywords

APOLIPOPROTEIN B; EZETIMIBE; EZETIMIBE PLUS TETRAHYDROLIPSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RIMONABANT; RIMONABANT PLUS TETRAHYDROLIPSTATIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTICAL PARAMETERS; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; LOW CALORY DIET; MALE; OBESITY; OPEN STUDY; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BODY WEIGHT; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LACTONES; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PIPERIDINES; PYRAZOLES;

EID: 70449686256     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248409343935     Document Type: Article

References (36)

1. Klein S., Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004 ; 110 (18). 2952-2967.
2. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005 ; 294 (14). 1773-1781.
3. Liberopoulos EN, Mikhailidis DP, Elisaf MS Diagnosis and management of the metabolic syndrome in obesity. Obes Rev. 2005 ; 6 (4). 283-296.
4. Wadden TA, Butryn ML Behavioral treatment of obesity. Endocrinol Metab Clin North Am. 2003 ; 32 (4). 981-1003.
5. Kiortsis DN, Filippatos TD, Elisaf MS The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab. 2005 ; 31 (1). 15-22.
6. Nakou ES, Filippatos TD, Georgoula M., et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin. 2008 ; 24 (7). 1919-1929.
7. Pagotto U., Marsicano G., Cota D., Lutz B., Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006 ; 27 (1). 73-100.
8. Van Gaal L., Pi- Sunyer X., Despres JP, McCarthy C., Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care. 2008 ; 31 (Suppl 2). S229-240.
9. Press Release-The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. http://www.emea.europa.eu/. Accessed June 20, 2008.
10. Baigent C., Keech A., Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366 (9493). 1267-1278.
11. Kiortsis DN, Filippatos TD, Mikhailidis DP, Elisaf MS, Liberopoulos EN Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis. 2007 ; 195 (1). 7-16.
12. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin. 2005 ; 21 (6). 959-969.
13. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 ; 285 (19). 2486-2497.
14. Florentin M., Liberopoulos EN, Elisaf MS Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract. 2008 ; 62 (1). 88-96.
15. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 ; 112 (17). 2735-2752.
16. Zigmond AS, Snaith RP The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 ; 67 (6). 361-370.
17. Davidson MH, Hauptman J., DiGirolamo M., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999 ; 281 (3). 235-242.
18. Sjostrom L., Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998 ; 352 (9123). 167-172.
19. Bakris G., Calhoun D., Egan B., Hellmann C., Dolker M., Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002 ; 20 (11). 2257-2267.
20. Swinburn BA, Carey D., Hills AP, et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab. 2005 ; 7 (3). 254-262.
21. Guy-Grand B., Drouin P., Eschwege E., Gin H., Joubert JM, Valensi P. Effects of orlistat on obesity-related diseases-a six-month randomized trial. Diabetes Obes Metab. 2004 ; 6 (5). 375-383.
22. Muls E., Kolanowski J., Scheen A., Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord. 2001 ; 25 (11). 1713-1721.
23. Noakes M., Keogh JB, Foster PR, Clifton PM Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr. 2005 ; 81 (6). 1298-1306.
24. Sartorio A., Lafortuna CL, Vangeli V., Tavani A., Bosetti C., La Vecchia C. Short-term changes of cardiovascular risk factors after a non-pharmacological body weight reduction program. Eur J Clin Nutr. 2001 ; 55 (10). 865-869.
25. Florentin M., Liberopoulos EN, Filippatos TD, et al. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/ obese patients: a pilot study. Expert Opin Pharmacother. 2008 ; 9 (16). 2741-2750.
26. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M., Mikhailidis DP, Elisaf MS Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin. 2005 ; 21 (12). 1997-2006.
27. Kalogirou M., Tsimihodimos V., Gazi I., et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin. 2007 ; 23 (5). 1169-1176.
28. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin. 2007 ; 23 (9). 2183-2192.
29. Kastelein JJ, van der Steeg WA, Holme I., et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008 ; 117 (23). 3002-3009.
30. Gazi IF, Tsimihodimos V., Tselepis AD, Elisaf M., Mikhailidis DP Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther. 2007 ; 7 (1). 53-72.
31. Florentin M., Liberopoulos EN, Wierzbicki AS, Mikhailidis DP Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008 ; 23 (4). 370-378.
32. McQueen MJ, Hawken S., Wang X., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008 ; 372 (9634). 224-233.
33. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology. 2004 ; 55 (6). 589-612.
34. Koenig W., Lowel H., Baumert J., Meisinger C. C-reactive protein modulates risk prediction based on the Framing-ham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004 ; 109 (11). 1349-1353.
35. Ridker PM, Danielson E., Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359 (21). 2195-2207.
36. Nissen SE, Nicholls SJ, Wolski K., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008 ; 299 (13). 1547-1560.